News

The New England Journal of Medicine2mon
Adrenomedullary Dysplasia and Hypofunction in Patients with Classic 21-Hydroxylase Deficiency | NEJM - New England Journal of Medicine
Ehrhart-Bornstein, M, Breidert, M, Guadanucci, P, et al. 17 alpha-Hydroxylase and chromagranin A in 6th week human fetal adrenals. Horm Metab Res 1997;29:30-32 Crossref ...
Healio2mon
Are non-glucocorticoid therapies needed for optimal care of 21-hydroxylase deficiency? - Healio
Yes, I do think we need non-glucocorticoid forms of therapy to treat 21-hydroxylase deficiency congenital adrenal hyperplasia.The most common form of congenital adrenal hyperplasia (CAH) is a ...
ascopubs.org18y
Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC) | Journal ... - ASCO Publications
Background: Abiraterone acetate (Ab) is an oral inhibitor of 17 alpha hydroxylase and C17,20-Lyase, which are important in adrenal androgen synthesis. A phase I study was undertaken to define the ...
ascopubs.org17y
Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-alpha hydroxylase C17,20-lyase inhibitor in castration resistant ... - ASCO Publications
Background: Abiraterone acetate (AA) is an inhibitor of CYP 17 (17 α hydroxylase and C17,20-Lyase), a dual enzyme responsible for androgen synthesis. The mechanism of action of abiraterone is similar ...
National Institute for Health and Care Excellence9y
2 The technology | Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | Guidance | NICE
Abiraterone acetate (Zytiga, Janssen) is a selective androgen synthesis inhibitor that works by blocking cytochrome P450 17 alpha‑hydroxylase. It blocks androgen production in the testes and adrenal ...